$TGTX News Article - TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
https://marketwirenews.com/news-releases/tg-t...83057.html